Schulz S C, Schulz P M, Dommisse C, Hamer R M, Blackard W G, Narasimhachari N, Friedel R O
Psychiatry Res. 1985 Jun;15(2):97-108. doi: 10.1016/0165-1781(85)90045-9.
The behavioral and biological responses to d-amphetamine have been studied extensively in patients with schizophrenia and depression, and to a lesser degree in bipolar affective disorders. Because of theories linking borderline personality disorder to those illnesses, amphetamine, 30 mg, p.o., was administered to eight borderline patients in a double-blind, placebo-controlled study and the results were compared to the responses of normal subjects under identical conditions. Amphetamine led to symptoms of psychosis in four out of eight (50%) borderline patients. No normal subject became psychotic during the procedure. Global ratings of well-being were significantly elevated in the borderline group compared to the normal group. In addition the global response was highly inversely correlated with the patient's score on the Diagnostic Interview for Borderlines. Borderline patients had a nonsignificantly decreased growth hormone response following amphetamine compared to normals. Thus, borderline patients appear to be pharmacodynamically separable from normals.
对精神分裂症和抑郁症患者对右旋苯丙胺的行为和生物学反应已进行了广泛研究，而对双相情感障碍患者的研究程度相对较低。由于有理论将边缘型人格障碍与这些疾病联系起来，在一项双盲、安慰剂对照研究中，对8名边缘型患者口服30毫克苯丙胺，并将结果与相同条件下正常受试者的反应进行比较。苯丙胺导致8名（50%）边缘型患者中的4名出现精神病症状。在此过程中没有正常受试者出现精神病症状。与正常组相比，边缘型组的总体幸福感评分显著升高。此外，总体反应与患者在边缘型人格障碍诊断访谈中的得分高度负相关。与正常人相比，边缘型患者在服用苯丙胺后生长激素反应有非显著性降低趋势。因此，边缘型患者在药效学上似乎与正常人不同。
